Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria.
Albumin
Non-selective beta blockers
Practice
Survey
Transjugular intrahepatic portosystemic shunt
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
04
08
2020
accepted:
03
11
2020
pubmed:
4
12
2020
medline:
15
5
2021
entrez:
3
12
2020
Statut:
ppublish
Résumé
Portal hypertension (PH) causes severe complications in patients with liver cirrhosis, such as variceal bleeding and ascites; however, data on the knowledge and perceptions on guideline recommendations for the management of varices and the use of albumin is scarce. We designed two structured surveys on (i) the management of varices and (ii) the use of albumin for Austrian physicians of specialized Gastro-Intestinal (GI) centers. The interviewed physicians were confronted spontaneously and provided ad hoc responses to the questionnaire. In total, 158 surveys were completed. Interestingly, many specialists (30%) would recommend a follow-up gastroscopy after 1 year in patients with compensated cirrhosis without varices (i.e., overtreatment). For small varices, 81.5% would use non-selective beta blockers (NSBB) for primary prophylaxis (PP). For PP in patients with large varices, endoscopic band ligation (EBL) plus NSBB was preferred by 51.4% (i.e., overtreatment). Knowledge on the indication criteria for early TIPS (transjugular intrahepatic portosystemic shunt) was reported by 54.3%, but only 20% could report these criteria correctly. The majority (87.1%) correctly indicated a preference to use NSBB and EBL for secondary prophylaxis (SP). The majority of participating gastroenterologists reported no restrictions on the use of albumin (89.8%) in their hospitals. Of the interviewed specialists, 63.6% would use albumin in patients with SBP; however, only 11.4% would use the doses recommended by guidelines. The majority of specialists indicated using albumin at the recommended doses for hepatorenal syndrome (HRS-AKI, 86.4%) and for large volume paracentesis (LVP, 73.3%). The individual responses regarding albumin use for infections/sepsis, hyponatremia, renal impairment, and encephalopathy were heterogeneous. The reported management of PH and varices is mostly adherent to guidelines, but endoscopic surveillance in patients without varices is too intense and EBL is overused in the setting of PP. Knowledge on the correct use of early TIPS must be improved among Austrian specialists. Albumin use is widely unrestricted in Austria; however, albumin is often underdosed in established indications.
Sections du résumé
BACKGROUND
BACKGROUND
Portal hypertension (PH) causes severe complications in patients with liver cirrhosis, such as variceal bleeding and ascites; however, data on the knowledge and perceptions on guideline recommendations for the management of varices and the use of albumin is scarce.
METHODS
METHODS
We designed two structured surveys on (i) the management of varices and (ii) the use of albumin for Austrian physicians of specialized Gastro-Intestinal (GI) centers. The interviewed physicians were confronted spontaneously and provided ad hoc responses to the questionnaire.
RESULTS
RESULTS
In total, 158 surveys were completed. Interestingly, many specialists (30%) would recommend a follow-up gastroscopy after 1 year in patients with compensated cirrhosis without varices (i.e., overtreatment). For small varices, 81.5% would use non-selective beta blockers (NSBB) for primary prophylaxis (PP). For PP in patients with large varices, endoscopic band ligation (EBL) plus NSBB was preferred by 51.4% (i.e., overtreatment). Knowledge on the indication criteria for early TIPS (transjugular intrahepatic portosystemic shunt) was reported by 54.3%, but only 20% could report these criteria correctly. The majority (87.1%) correctly indicated a preference to use NSBB and EBL for secondary prophylaxis (SP). The majority of participating gastroenterologists reported no restrictions on the use of albumin (89.8%) in their hospitals. Of the interviewed specialists, 63.6% would use albumin in patients with SBP; however, only 11.4% would use the doses recommended by guidelines. The majority of specialists indicated using albumin at the recommended doses for hepatorenal syndrome (HRS-AKI, 86.4%) and for large volume paracentesis (LVP, 73.3%). The individual responses regarding albumin use for infections/sepsis, hyponatremia, renal impairment, and encephalopathy were heterogeneous.
CONCLUSION
CONCLUSIONS
The reported management of PH and varices is mostly adherent to guidelines, but endoscopic surveillance in patients without varices is too intense and EBL is overused in the setting of PP. Knowledge on the correct use of early TIPS must be improved among Austrian specialists. Albumin use is widely unrestricted in Austria; however, albumin is often underdosed in established indications.
Identifiants
pubmed: 33270161
doi: 10.1007/s00508-020-01769-9
pii: 10.1007/s00508-020-01769-9
pmc: PMC8116244
doi:
Substances chimiques
Albumins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-431Références
J Hepatol. 2012 Oct;57(4):759-65
pubmed: 22732511
Hepatology. 2013 Nov;58(5):1836-46
pubmed: 23423799
N Engl J Med. 2010 Jun 24;362(25):2370-9
pubmed: 20573925
Gut. 2013 Nov;62(11):1634-41
pubmed: 23250049
Biochim Biophys Acta. 2013 Dec;1830(12):5465-72
pubmed: 23644037
J Hepatol. 2005 Jul;43(1):167-76
pubmed: 15925423
J Hepatol. 2013 May;58(5):911-21
pubmed: 23262249
J Hepatol. 2017 Sep 13;68(1):73-81
pubmed: 28918131
Gastroenterology. 2019 Jul;157(1):149-162
pubmed: 30905652
Liver Int. 2020 Jan;40(1):194-204
pubmed: 31444993
Wien Klin Wochenschr. 2012 Jun;124(11-12):395-402
pubmed: 22699260
N Engl J Med. 2004 May 27;350(22):2247-56
pubmed: 15163774
J Hepatol. 2016 Mar;64(3):574-82
pubmed: 26519600
J Hepatol. 2017 Jul;67(1):40-46
pubmed: 28213164
Wien Klin Wochenschr. 2017 Nov;129(Suppl 3):135-158
pubmed: 29063233
Gastroenterology. 2008 May;134(5):1352-9
pubmed: 18471512
Dig Liver Dis. 2011 May;43(5):345-51
pubmed: 21095166
Dig Liver Dis. 2017 Jan;49(1):3-10
pubmed: 27717792
Hepatol Int. 2016 Jan;10(1):124-32
pubmed: 26420218
Lancet. 2018 Jun 16;391(10138):2417-2429
pubmed: 29861076
Hepatology. 2017 Jan;65(1):310-335
pubmed: 27786365
Aliment Pharmacol Ther. 2018 Apr;47(8):1224-1225
pubmed: 29574874
J Hepatol. 2016 Oct;65(4):692-699
pubmed: 27242316
Aliment Pharmacol Ther. 2018 Apr;47(7):966-979
pubmed: 29388229
Can J Gastroenterol. 2006 Aug;20(8):531-4
pubmed: 16955150
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Hepatol. 2015 Nov;63(5):1272-84
pubmed: 26192220
Hepatology. 2019 Jan;69(1):282-293
pubmed: 30014519
J Hepatol. 2017 Apr;66(4):849-859
pubmed: 27864004
Gut. 2016 Jun;65(6):1058-60
pubmed: 26933172
Clin Gastroenterol Hepatol. 2010 Aug;8(8):703-8
pubmed: 20226879
Gut. 2012 Jul;61(7):967-9
pubmed: 22234982
Hepatology. 2003 Sep;38(3):599-612
pubmed: 12939586
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
Eur J Gastroenterol Hepatol. 2012 May;24(5):551-7
pubmed: 22356784
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7674-7
pubmed: 1502182
Liver Int. 2019 Feb;39(2):290-298
pubmed: 30248224
Am J Med Qual. 2016 Mar-Apr;31(2):118-24
pubmed: 25348546
Dig Liver Dis. 2017 Dec;49(12):1360-1367
pubmed: 28869158
Hepatol Int. 2013 Mar;7(1):248-56
pubmed: 26201639
Scand J Gastroenterol. 2017 Sep;52(9):1008-1015
pubmed: 28532189
Liver Int. 2015 Feb;35(2):335-43
pubmed: 24620819
Gut. 2016 Aug;65(8):1393-4
pubmed: 27207973
J Hepatol. 2020 Oct;73(4):829-841
pubmed: 32298768
J Hepatol. 2020 Mar;72(3):463-471
pubmed: 31622697
Gut. 2017 Jul;66(7):1347-1349
pubmed: 27694143
PLoS One. 2018 Jan 9;13(1):e0189414
pubmed: 29315304
Gut. 2015 Jul;64(7):1111-9
pubmed: 25281417
Nat Med. 2014 May;20(5):518-23
pubmed: 24728410
Gut. 2016 Jul;65(7):1228-30
pubmed: 26935875
Gastroenterology. 2014 Jun;146(7):1680-90.e1
pubmed: 24631577
J Clin Gastroenterol. 2017 Oct;51(9):831-838
pubmed: 28787354
Hepatology. 2010 Sep;52(3):1017-22
pubmed: 20583214
Aliment Pharmacol Ther. 2019 Sep;50(6):696-706
pubmed: 31373713
Gut. 2015 Jul;64(7):1015-7
pubmed: 25398769
Lancet. 2019 Apr 20;393(10181):1597-1608
pubmed: 30910320
Wien Klin Wochenschr. 2020 Jan;132(1-2):1-11
pubmed: 31912289
Am J Gastroenterol. 2005 Apr;100(4):797-804
pubmed: 15784021
Dig Liver Dis. 2014 May;46(5):419-26
pubmed: 24433997
Aliment Pharmacol Ther. 2018 Apr;47(8):1162-1169
pubmed: 29492989
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):e10-8
pubmed: 26671516
Gastroenterology. 1981 Apr;80(4):800-9
pubmed: 6970703
J Hepatol. 2020 Dec;73(6):1404-1414
pubmed: 32446716
JHEP Rep. 2020 May 23;2(4):100122
pubmed: 32671331
Eur J Gastroenterol Hepatol. 2015 Aug;27(8):928-32
pubmed: 25951490
Hepatology. 2006 Mar;43(3):500-5
pubmed: 16496319
N Engl J Med. 1988 Oct 13;319(15):983-9
pubmed: 3262200
J Hepatol. 2015 Sep;63(3):743-52
pubmed: 26047908
Aliment Pharmacol Ther. 2017 Jan;45(1):139-149
pubmed: 27910154
Semin Liver Dis. 2020 Aug;40(3):240-255
pubmed: 32557480
Hepatology. 2010 Jul;52(1):230-7
pubmed: 20578138